Effects of hypoglycaemic therapy on frailty: a multi-dimensional perspective

References

• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. DOI:10.1016/j.diabres.2018.02.023.
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Abdelhafiz AH, Rodríguez-Mañas L. Frailty and sarcopenia - newly emerging and high impact complications of diabetes. J Diabetes Complications. 2017;31(9):1465–1473.
   PubMed Web of Science ®Google Scholar
• Hanlon P, Jani BD, Butterly E, et al. An analysis of frailty and multimorbidity in 20,566 UK Biobank participants with type 2 diabetes. Commun Med. 2021;28. DOI:10.1038/s43856-021-00029-9.
   Google Scholar
• Espeland MA, Justice JN, Bahnson J, et al. Look AHEAD Research Group. Eight year changes in multimorbidity and frailty in adults with type 2 diabetes mellitus: associations with cognitive and physical function and mortality. J Gerontol A Biol Sci Med Sci. 2021;glab342. DOI:10.1093/gerona/glab342.
   Web of Science ®Google Scholar
• Nguyen TN, Harris K, Woodward M, et al. The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care. 2021;44(7):1622–1629.
   PubMed Web of Science ®Google Scholar
• Sable-Morita S, Tanikawa T, Satake S, et al. Microvascular complications and frailty can predict adverse outcomes in older patients with diabetes. Geriatr Gerontol Int. 2021;21(4):359–363.
   PubMed Web of Science ®Google Scholar
• Ferri-Guerra J, Aparicio-Ugarriza R, Salguero D, et al. The association of frailty with hospitalizations and mortality among community dwelling older adults with diabetes. J Frailty Aging. 2020;9(2):94–100.
   PubMed Web of Science ®Google Scholar
• Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm-issues and controversies. J Gerontol A Biol Sci Med Sci. 2009;62A:731–737.
   Google Scholar
• Cardiovascular Health Study Collaborative Research Group; Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156.
   PubMed Web of Science ®Google Scholar
• Khezrian M, Myint PK, McNeil C, et al. A review of frailty syndrome and its physical, cognitive and emotional domains in the elderly. Geriatrics (Basel). 2017;2(4):36.
   PubMedGoogle Scholar
• Abdelhafiz AH, Davies PC, Sinclair AJ. Triad of impairment in older people with diabetes-reciprocal relations and clinical implications. Diabetes Res Clin Pract. 2020;161:108065. DOI:10.1016/j.diabres.2020.108065.
   PubMed Web of Science ®Google Scholar
• Thein FS, Li Y, Nyunt MSZ, et al. Physical frailty and cognitive impairment is associated with diabetes and adversely impact functional status and mortality. Postgrad Med. 2018;130(6):561–567.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Sinclair AJ. Cardio-renal protection in older people with diabetes with frailty and medical comorbidities-A focus on the new hypoglycaemic therapy. J Diabetes Complications. 2020;34(9):107639.
   PubMed Web of Science ®Google Scholar
• Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the cardiovascular health study. Circulation. 2011;123(8):858–865.
   PubMed Web of Science ®Google Scholar
• Chhetri JK, Zheng Z, Xu X, et al. The prevalence and incidence of frailty in pre-diabetic and diabetic community dwelling older population: results from Beijing longitudinal study of aging II (BLSA-II). BMC Geriatr. 2017;17(1):47.
   PubMedGoogle Scholar
• Howrey BT, Al Snih S, Markides KS. Frailty and diabetes among Mexican American older adults. Ann Epidemiol. 2018;28(7):421–426.
   PubMed Web of Science ®Google Scholar
• García-Esquinas E, Graciani A, Guallar-Castillón P, et al. Diabetes and risk of frailty and its potential mechanisms: a prospective cohort study of older adults. J Am Med Dir Assoc. 2015;16(9):748–754.
   PubMed Web of Science ®Google Scholar
• Castrejón-Pérez RC, Gutiérrez-Robledo LM, Cesari M, et al. Diabetes mellitus, hypertension and frailty: a population-based, cross-sectional study of Mexican older adults. Geriatr Gerontol Int. 2017;17(6):925–930.
   PubMed Web of Science ®Google Scholar
• Castrejon-Perez RC, Aguilar-Salinas CA, Gutierrez-Robledo LM, et al. Frailty, diabetes, and the convergence of chronic disease in an age-related condition: a population-based nationwide cross-sectional analysis of the Mexican nutrition and health survey. Aging Clin Exp Res. 2018;30(8):935–941.
   PubMed Web of Science ®Google Scholar
• Ninomiya T. Diabetes mellitus and dementia. Curr Diab Rep. 2014;14(5):487.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen C, Hua S, et al. An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract. 2017;124:41–47.
   PubMed Web of Science ®Google Scholar
• Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6):540–548.
   PubMed Web of Science ®Google Scholar
• Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505–512.
   PubMed Web of Science ®Google Scholar
• Kloppenborg RP, van den Berg E, Kappelle LJ, et al. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol. 2008;585(1):97–108.
   PubMed Web of Science ®Google Scholar
• Davis WA, Zilkens RR, Starkstein SE, et al. Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle diabetes study phase I. Diabetologia. 2017;60(1):89–97.
   PubMed Web of Science ®Google Scholar
• Meng XF, Yu JT, Wang HF, et al. Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;42(4):1295–1310.
   PubMed Web of Science ®Google Scholar
• Rawlings AM, Sharrett AR, Schneider ALC, et al. Diabetes in midlife and cognitive change over 20 years: the atherosclerosis risk in communities neurocognitive study. Ann Intern Med. 2014;161(11):785–793.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300–307.
   PubMed Web of Science ®Google Scholar
• Roberts RO, Knopman DS, Geda YE, et al. Association of diabetes with amnestic and non-amnestic mild cognitive impairment. Alzheimers Dement. 2014;10(1):18–26.
   PubMed Web of Science ®Google Scholar
• Cooper C, Sommerlad A, Lyketsos CG, et al. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(4):323–334.
   PubMed Web of Science ®Google Scholar
• Li JQ, Tan L, Wang HF, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry. 2016;87(5):476–484.
   PubMed Web of Science ®Google Scholar
• Kingshuk P, Mukadam N, Petersen I, et al. Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2018;53(11):1149–1160.
   PubMed Web of Science ®Google Scholar
• Zhuang QS, Shen L, Ji HF. Quantitative assessment of the bidirectional relationships between diabetes and depression. Oncotarget. 2017;8(14):23389–23400.
   PubMedGoogle Scholar
• Syed SH, Abdullah AM, Alexandra MC, et al. Incidence and risk of depression associated with diabetes in adults: evidence from longitudinal studies. Community Ment Health J. 2015;51(2):204–210.
   PubMed Web of Science ®Google Scholar
• Chireh B, Li M, D’Arcy C. Diabetes increases the risk of depression: a systematic review, meta-analysis and estimates of population attributable fractions based on prospective studies. Prev Med Rep. 2019;14:100822.
   PubMedGoogle Scholar
• de Jonge P, Roy JF, Saz P, et al. Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia. 2006;49(11):2627–2633.
   PubMed Web of Science ®Google Scholar
• Maraldi C, Volpato S, Penninx BW, et al. Diabetes mellitus, glycemic control, and incident depressive symptoms among 70 to 79-year-old persons: the health, aging, and body composition study. Arch Intern Med. 2007;167(11):1137–1144.
   PubMedGoogle Scholar
• Tong A, Wang X, Li F, et al. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol. 2016;53(4):589–598.
   PubMed Web of Science ®Google Scholar
• Meurs M, Roest AM, Wolffenbuttel BH, et al. Association of depressive and anxiety disorders with diagnosed versus undiagnosed diabetes: an epidemiological study of 90,686 participants. Psychosom Med. 2016;78(2):233–241.
   PubMed Web of Science ®Google Scholar
• Almeida OP, McCaul K, Hankey GJ, et al. Duration of diabetes and its association with depression in later life: the Health In Men Study (HIMS). Maturitas. 2016;86:3–9.
   PubMed Web of Science ®Google Scholar
• Panza F, Seripa D, Solfrizzi V, et al. Targeting cognitive frailty: clinical and neurobiological roadmap for a single complex phenotype. J Alzheimer’s Dis. 2015;47(4):793–813.
   PubMed Web of Science ®Google Scholar
• Robertsona DA, Savva GM, Kenny RA. Frailty and cognitive impairment—A review of the evidence and causal mechanisms. Ageing Res Rev. 2013;12(4):840–851.
   PubMed Web of Science ®Google Scholar
• Lohman M, Dumenci L, Mezuk B. Depression and frailty in late life: evidence for a common vulnerability. J Gerontol B Psychol Sci Soc Sci. 2016;71(4):630–640.
   PubMed Web of Science ®Google Scholar
• Vaughan L, Corbin AL, Goveas JS. Depression and frailty in later life: a systematic review. Clin Interv Aging. 2015;10:1947–1958.
   PubMed Web of Science ®Google Scholar
• Soysal P, Veronese N, Thompson T, et al. Relationship between depression and frailty in older adults: a systematic review and meta-analysis. Ageing Res Rev. 2017;36:78–87. DOI:10.1016/j.arr.2017.03.005.
   PubMed Web of Science ®Google Scholar
• Godin J, Armstrong JJ, Rockwood K, et al. Dynamics of frailty and cognition after age 50: why it matters that cognitive decline is mostly seen in old age. J Alzheimers Dis. 2017;58(1):231–242.
   PubMed Web of Science ®Google Scholar
• Liu YC, Meguro K, Nakamura K, et al. Depression and Dementia in old-old population: history of depression may be associated with dementia onset. The Tome project. Front Aging Neurosci. 2017; 9:335. doi: 10.3389/fnagi.2017.00335
   PubMed Web of Science ®Google Scholar
• Li G, Wang LY, Shofer JB, et al. Temporal relationship between depression and dementia–findings from a large community-based 15 year follow-up study. Arch Gen Psychiatry. 2011;68(9):970–977.
   PubMed Web of Science ®Google Scholar
• Aichele S, Ghisletta P. Memory deficits precede increases in depressive symptoms in later adulthood. J Gerontol B Psychol Sci Soc Sci. 2018. DOI:10.1093/geronb/gbx183
   Web of Science ®Google Scholar
• Veronese N, Stubbs B, Fontana L, et al. Frailty is associated with an increased risk of incident type 2 diabetes in the elderly. J Am Med Dir Assoc. 2016;17(10):902–907.
   PubMed Web of Science ®Google Scholar
• Twig G, Gluzman I, Tirosh A, et al. Cognitive function and the risk for diabetes among young men. Diabetes Care. 2014;37(11):2982–2988.
   PubMed Web of Science ®Google Scholar
• Huang C-F, Shiao M-S, Mao T-Y. Effects of low-dose metformin on pre-frailty among middle-aged and elderly pre-diabetic people. JCSM Rapid Communications. 2022;5(1):33–39
   Google Scholar
• Hazuda HP, Pan Q, Florez H, et al. Association of intensive lifestyle and metformin interventions with frailty in the diabetes prevention program outcomes study. J Gerontol A Biol Sci Med Sci. 2021;76(5):929–936.
   PubMed Web of Science ®Google Scholar
• Baskaran D, Aparicio-Ugarriza R, Ferri-Guerra J, et al. Is there an association between metformin exposure and frailty? Gerontol Geriatr Med. 2020;6:2333721420924956.
   Web of Science ®Google Scholar
• Wang CP, Lorenzo C, Habib SL, et al. Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. J Diabetes Complications. 2017;31(4):679–686.
   PubMed Web of Science ®Google Scholar
• Sumantri S, Setiati S, Purnamasari D, et al. Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes. Acta Med Indones. 2014;46(3):183–188.
   PubMedGoogle Scholar
• Wang CP, Lorenzo C, Espinoza SE. Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. J Endocrinol Diabetes Obes. 2014;2(2):1031.
   PubMedGoogle Scholar
• Lee CG, Schwartz AV, Yaffe K, et al. Changes in physical performance in older women according to presence and treatment of diabetes mellitus. J Am Geriatr Soc. 2013;61(11):1872–1878.
   PubMed Web of Science ®Google Scholar
• Kuan YC, Huang KW, Lin CL, et al. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):77–83.
   PubMedGoogle Scholar
• Akimoto H, Negishi A, Oshima S, et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. Am J Alzheimers Dis Other Demen. 2020;35:1533317519899546.
   Web of Science ®Google Scholar
• Mone P, Lombardi A, Gambardella J, et al. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. Diabetes Care. 2022;45(5):1247–1251.
   PubMed Web of Science ®Google Scholar
• Ng TP, Feng L, Yap KB, et al. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61–68.
   PubMed Web of Science ®Google Scholar
• Cheng C, Lin CH, Tsai YW, et al. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci. 2014;69(10):1299–1305.
   PubMed Web of Science ®Google Scholar
• Moore EM, Mander AG, Ames D, et al.; AIBL Investigators. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013;36:2981–2987.
   PubMed Web of Science ®Google Scholar
• Herath PM, Cherbuin N, Eramudugolla R, et al. The effect of diabetes medication on cognitive function: evidence from the PATH through life study. Biomed Res Int. 2016;2016:7208429.
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Ogawa M, Honjo J, et al. Risk factors associated with abnormal cognition in Japanese outpatients with diabetes, hypertension or dyslipidemia. Diabetol Int. 2015;6(4):268–274.
   Web of Science ®Google Scholar
• Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284–294.
   PubMed Web of Science ®Google Scholar
• Kim YG, Jeon JY, Kim HJ, et al. Risk of dementia in older patients with type 2 diabetes on dipeptidyl-peptidase IV inhibitors versus sulfonylureas: a real-world population-based cohort study. J Clin Med. 2019;8(1):28.
   Web of Science ®Google Scholar
• Isik AT, Soysal P, Yay A, et al. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res Clin Pract. 2017;123:192–198.
   PubMed Web of Science ®Google Scholar
• Rizzo MR, Barbieri M, Boccardi V, et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci. 2014;69(9):1122–1131.
   PubMed Web of Science ®Google Scholar
• Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19(7):582–590.
   PubMed Web of Science ®Google Scholar
• Perna S, Mainardi M, Astrone P, et al. 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. Clin Pharmacol. 2018;10:141–151.
   PubMed Web of Science ®Google Scholar
• Huang CC, Chung CM, Leu HB, et al. Diabetes mellitus and the risk of Alzheimer’s disease: a nationwide population-based study. PLoS One. 2014;9(1):e87095.
   PubMed Web of Science ®Google Scholar
• Bohlken J, Jacob L, Kostev K. Association between the use of antihyperglycemic drugs and dementia risk: a case-control study. J Alzheimers Dis. 2018;66(2):725–732.
   PubMed Web of Science ®Google Scholar
• Weinstein G, Davis-Plourde KL, Conner S, et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: pooled analysis from 5 cohorts. PLoS One. 2019;14(2):e0212293.
   PubMed Web of Science ®Google Scholar
• Zhou JB, Tang X, Han M, et al. Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis. Metabolism. 2020 Aug;109:154265. DOI:10.1016/j.metabol.2020.154265.
   PubMed Web of Science ®Google Scholar
• Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 2014;41(9):650–656.
   PubMed Web of Science ®Google Scholar
• Wium-Andersen IK, Osler M, Jørgensen MB, et al. Diabetes, antidiabetic medications and risk of depression-A population-based cohort and nested case-control study. Psychoneuroendocrinology. 2022;140:105715.
   PubMed Web of Science ®Google Scholar
• Kessing LV, Rytgaard HC, Ekstrøm CT, et al. Antidiabetes agents and incident depression: a nationwide population-based study. Diabetes Care. 2020;43(12):3050–3060.
   PubMed Web of Science ®Google Scholar
• Moulton CD, Pickup JC, Amiel SA, et al. Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: findings from the South London Diabetes (SOUL-D) Study. Prim Care Diabetes. 2016;10(2):156–159.
   PubMed Web of Science ®Google Scholar
• Gamble JM, Chibrikov E, Midodzi WK, et al. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK clinical practice research datalink. BMJ Open. 2018;8(10):e023830.
   PubMed Web of Science ®Google Scholar
• Akimoto H, Tezuka K, Nishida Y, et al. Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: a retrospective cohort study. Pharmacol Res Perspect. 2019;7(6):e00536.
   PubMed Web of Science ®Google Scholar
• Oliveira RA, Tostes M, Queiroz VA, et al. Insulin mediated improvement in glycemic control in elderly with type 2 diabetes mellitus can improve depressive symptoms and does not seem to impair health-related quality of life. Diabetol Metab Syndr. 2015;7(1):55.
   PubMedGoogle Scholar
• Laksmi PW, Setiati S, Tamin TZ, et al. Effect of metformin on handgrip strength, gait speed, myostatin serum level, and health-related quality of life: a double blind randomized controlled trial among non-diabetic pre-frail elderly patients. Acta Med Indones. 2017;49(2):118–127.
   PubMedGoogle Scholar
• Piskovatska V, Stefanyshyn N, Storey KB, et al. Metformin as a geroprotector: experimental and clinical evidence. Biogerontology. 2019;20(1):33–48.
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER, Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.
   PubMed Web of Science ®Google Scholar
• Barzilai N, Crandall JP, Kritchevsky SB, et al. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060–1065.
   PubMed Web of Science ®Google Scholar
• Mele A, Calzolaro S, Cannone G, et al. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect. 2014;2(1):e00028.
   PubMedGoogle Scholar
• Aghili R, Malek M, Valojerdi AE, et al. Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin. J Diabetes Metab Disord. 2014;13(1):88.
   PubMedGoogle Scholar
• Ikejima S, Kond S, Saka T, et al. Novel approach to sarcopenia in diabetic patients treated with GLP-1 receptor agonists (GLP-1RA). Diabetes. 2018;67(Supplement1). DOI:10.2337/db18-673-P
   Google Scholar
• Sasaki T, Sugawara M, Fukuda M. Sodium‐glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the components of weight loss in Japanese patients with type 2 diabetes mellitus) study. J Diabetes Investig. 2019;10(1):108–117.
   PubMed Web of Science ®Google Scholar
• Bouchi R, Terashima M, Sasahara Y, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16(1):32.
   PubMedGoogle Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA‐SU): 52 week results from a randomised, double‐blind, phase 3 non‐inferiority trial. Lancet. 2013;382(9896):941–950.
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018;25(6):467–476.
   PubMed Web of Science ®Google Scholar
• Sano M, Meguro S, Kawai T, et al. Increased grip strength with sodium-glucose cotransporter 2. J Diabetes. 2016;8(5):736–737.
   PubMed Web of Science ®Google Scholar
• Mone P, Varzideh F, Jankauskas SS, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79:1633–1643.
   PubMed Web of Science ®Google Scholar
• Abdulla H, Phillips B, Smith K, et al. Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. Curr Diabetes Rev. 2014;10(5):231–237.
   PubMedGoogle Scholar
• Avogaro A, Dardano A, de Kreutzenberg SV, et al. Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes Obes Metab. 2015;17(2):107–115.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz A, Bisht S, Kovacevic I, et al. Insulin in frail older people with type 2 diabetes—low threshold for therapy. Diabetology. 2022;3(2):369–383.
   Google Scholar
• Sinclair AJ, Pennells D, Abdelhafiz AH. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype. Aging Clin Exp Res. 2022;34(9):1949–1967.
   PubMed Web of Science ®Google Scholar
• Campbell JM, Stephenson MD, de Courten B, et al., Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J Alzheimers Dis. 2018;65(4):1225–1236.
   PubMed Web of Science ®Google Scholar
• Campbell JM, Bellman SM, Stephenson MD, et al. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev. 2017;40:31–44.
   PubMed Web of Science ®Google Scholar
• Huang YC, Hsu CC, Lin WC, et al. Effects of metformin on the cerebral metabolic changes in type 2 diabetic patients. ScientificWorldJournal. 2014;2014:694326.
   PubMedGoogle Scholar
• Mone P, Gambardella J, Pansini A, et al. Cognitive impairment in frail hypertensive elderly patients: role of hyperglycemia. Cells. 2021;10(8):2115.
   PubMed Web of Science ®Google Scholar
• Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms under- lying the rapid peroxisome proliferator-activated receptor-c-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci. 2012;32(30):10117–10128.
   PubMed Web of Science ®Google Scholar
• Nicolakakis N, Aboulkassim T, Ongali B, et al. Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator- activated receptor gamma agonist. J Neurosci. 2008;28(37):9287–9296.
   PubMed Web of Science ®Google Scholar
• Fujisawa K, Nishikawa T, Kukidome D, et al. TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun. 2009;379(1):43–48.
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740–751.
   PubMed Web of Science ®Google Scholar
• Salcedo I, Tweedie D, Li Y, et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol. 2012;166(5):1586–1599.
   PubMed Web of Science ®Google Scholar
• Mattishent K, Loke YK. Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people - Systematic review. J Diabetes Complications. 2018;32(8):805–812.
   PubMed Web of Science ®Google Scholar
• Chaytor NS, Barbosa-Leiker C, Ryan CM, et al. Clinically significant cognitive impairment in older adults with type 1 diabetes. J Diabetes Complications. 2019;33(1):91–97.
   PubMed Web of Science ®Google Scholar
• Pipatpiboon N, Pintana H, Pratchayasakul W, et al. DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur J Neurosci. 2013;37(5):839–849.
   PubMed Web of Science ®Google Scholar
• Pintana H, Apaijai N, Chattipakorn N, et al. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol. 2013;218(1):1–11.
   PubMed Web of Science ®Google Scholar
• Biswas SC, Buteau J, Greene LA. Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem Res. 2008;33(9):1845–1851.
   PubMed Web of Science ®Google Scholar
• Liu JH, Yin F, Guo LX, et al. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin. 2009;30(2):159–165.
   PubMed Web of Science ®Google Scholar
• Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.
   PubMed Web of Science ®Google Scholar
• Maimaiti S, Anderson KL, DeMoll C, et al. Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging. J Gerontol A Biol Sci Med Sci. 2016;71(1):30–39.
   PubMed Web of Science ®Google Scholar
• Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27:505–514.
   PubMed Web of Science ®Google Scholar
• Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord. 2009;113(1–2):1–20.
   PubMed Web of Science ®Google Scholar
• De la Roca-Chiapas JM, Hernandez-Gonzalez M, Candelario M, et al. Association between depression and higher glucose levels in middle-aged Mexican patients with diabetes. Rev Invest Clin. 2013;65(3):209–213.
   PubMedGoogle Scholar
• Watson K, Nasca C, Aasly L, et al. Insulin resistance, an unmasked culprit in depressive disorders: promises for interventions. Neuropharmacology. 2018;136:327–334.
   PubMed Web of Science ®Google Scholar
• Kim D-J, Yu JH, Shin M-S, et al. Hyperglycemia reduces efficiency of brain networks in subjects with type 2 diabetes. PLOS ONE. 2016;11(6):e0157268.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–858.
   PubMed Web of Science ®Google Scholar
• Mudgal J, Nampoothiri M, Basu Mallik S, et al. Possible involvement of metformin in downregulation of neuroinflammation and associated behavioural changes in mice. Inflammopharmacology. 2019;27(5):941–948.
   PubMed Web of Science ®Google Scholar
• Zemdegs J, Martin H, Pintana H, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39(30):5935–5948.
   PubMed Web of Science ®Google Scholar
• Grieco M, Giorgi A, Gentile MC, et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019;13:1112.
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Ashrafizadeh M, Henney NC, et al. Neuromodulatory effects of anti-diabetes medications: a mechanistic review. Pharmacol Res. 2020;152:104611. doi: 10.1016/j.phrs.2019.104611.
   PubMed Web of Science ®Google Scholar
• Jensen NJ, Wodschow HZ, Nilsson M, et al. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. 2020;21(22):8767.
   PubMed Web of Science ®Google Scholar
• Brietzke E, Mansur RB, Subramaniapillai M, et al. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Neurosci Biobehav Rev. 2018;94:11–16.
   PubMed Web of Science ®Google Scholar
• Milaneschi Y, Simmons WK, van Rossum EFC, et al. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24(1):18–33.
   PubMed Web of Science ®Google Scholar
• Reza M, Taylor C, Towse K, et al. Insulin improves well-being for selected elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;55(3):201–207.
   PubMed Web of Science ®Google Scholar
• Bai X, Liu Z, Li Z, et al. The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis. BMJ Open. 2018;8(11):e020062.
   PubMed Web of Science ®Google Scholar
• Pansini A, Lombardi A, Morgante M, et al. Hyperglycemia and physical impairment in frail hypertensive older adults. Front Endocrinol (Lausanne). 2022;13:831556.
   PubMed Web of Science ®Google Scholar
• Varonese N, Stubbs B, Noale M, et al. Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study. J Am Med Dir Assoc. 2017;18(7):624–628.
   PubMed Web of Science ®Google Scholar
• Morley JE, Malmstrom TK, Rodriguez-Manas L, et al. Frailty, sarcopenia and diabetes. J Am Med Dir Assoc. 2014;15(12):853–859.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Emmerton D, Sinclair AJ. New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status. Diabetes Res Clin Pract. 2020;169:108438.
   PubMed Web of Science ®Google Scholar
• Monti G, Gomes Moreira D, Richner M, et al. GLP-1 receptor agonists in neurodegeneration: neurovascular unit in the spotlight. Cells. 2022;11(13):2023.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Sinclair AJ. Cognitive frailty in older people with type 2 diabetes mellitus: the central role of hypoglycaemia and the need for prevention. Curr Diab Rep. 2019;19(4):15.
   PubMed Web of Science ®Google Scholar